Skip to main content
SpringerLink
Log in

Purine analogs sensitize the multidrug resistant cell line (NCI-H460/R) to doxorubicin and stimulate the cell growth inhibitory effect of verapamil

  • PRECLINICAL STUDIES
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

The resistant cell line NCI-H460/R and its counterpart NCI-H460 were used to investigate the ability of purine analogs to overcome multidrug resistance (MDR) that seriously limit the efficacy of lung cancer regimens with chemotherapeutic agents. Two purine analogs, sulfinosine (SF) and 8-Cl-cAMP, exerted dose-dependent effects on cell growth in both parental and resistant cell lines. They significantly decreased mdr1 expression in NCI-H460/R cells. Low concentrations (1 µM) of SF and 8-Cl-cAMP in combination with doxorubicin (DOX) exerted synergistic growth inhibition in both cell lines. Pretreatment with SF and 8-Cl-cAMP improved the sensitivity to DOX more than verapamil (VER), the standard modulator of MDR. The increased accumulation of DOX observed after the treatment with SF and 8-Cl-cAMP was consistent with the results obtained with VER. VER stimulated the effect of 8-Cl-cAMP on DOX cytotoxicity and mdr1 expression. Combinations of either SF or 8-Cl-cAMP with VER at clinically acceptable concentrations exhibited synergistic effects on cell growth inhibition in the resistant cell line. SF and 8-Cl-cAMP modulated MDR in NCI-H460/R cells, especially when applied before DOX administration. This feature, together with their ability to reverse MDR, renders the purine analogs (in combination with VER) as potential candidates for improving the clinical activity of existing lung cancer therapeutics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Yang P, Ebbert JO, Sun Z, Weinshilboum RM (2006) Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. J Clin Oncol 24:1761–1769

    Article  CAS  PubMed  Google Scholar 

  2. Leonessa F, Clarke R (2003) ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 10:43–73

    Article  CAS  PubMed  Google Scholar 

  3. Harbottle A, Daly AK, Atherton K, Campbell CF (2001) Role of glutathione-S- transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance. Int J Cancer 92:777–783

    Article  CAS  PubMed  Google Scholar 

  4. Magnarin M, Morelli M, Rosati A, Bartoli F, Candussio L, Giraldi T et al (2004) Induction of proteins involved in multidrug resistance (P-glycoprotein, MRP1, MRP2, LRP) and of CYP 3A4 by rifampicin in LLC-PK1 cells. Eur J Pharm 483:19–28

    Article  CAS  Google Scholar 

  5. Uchiyama-Kokubu N, Watanabe T (2001) Establishment and characterization of adriamycin-resistant human colorectal adenocarcinoma HCT-15 cell lines with multidrug resistance. Anti-Cancer Drugs 12:769–779

    Article  CAS  PubMed  Google Scholar 

  6. Pesic M, Markovic JZ, Jankovic D, Kanazir S, Markovic ID, Rakic L, Ruzdijic S (2006) Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugs. J Chemother 18(1):66–73

    CAS  PubMed  Google Scholar 

  7. Miraglia E, Viarisio D, Riganti C, Costamagna C, Ghigo D, Bosia A (2005) Na+/H + exchanger activity is increased in doxorubicin-resistant human colon cancer cells and its modulation modifies the sensitivity of the cells to doxorubicin. Int J Cancer 115:924–929

    Article  CAS  PubMed  Google Scholar 

  8. Pešić M, Andjelković T, Banković J, Marković ID, Rakić L, Ruždijić S (2009) Sulfinosine enhances doxorubicin efficacy through synergism and by reversing multidrug resistance in the human non-small cell lung carcinoma cell line (NCI-H460/ R). Invest New Drugs 27:99–110

    Article  PubMed  Google Scholar 

  9. Singh RP, Mallikarjuna GU, Sharma G, Dhanalakshimi S, Tyagi AK, Chan DCF, Agarwal C, Agarwal R (2004) Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor κB-mediated inducibile chemoresistance. Clin Cancer Res 10:8641–8647

    Article  CAS  PubMed  Google Scholar 

  10. Lay JD, Hong CC, Huang JS, Yang YY, Pao CY, Liu CH, Lai YP, Lai GM, Cheng AL, Su IJ, Chuang SE (2007) Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL. Cancer Res 67:3878–3887

    Article  CAS  PubMed  Google Scholar 

  11. Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP (2000) Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 87(2–3):227–253

    Article  CAS  PubMed  Google Scholar 

  12. Andjelkovic T, Pesic M, Bankovic J, Tanic N, Markovic ID, Ruzdijic S (2008) Synergistic effects of the purine analog sulfinosine and curcumin on the multidrug resistant human non-small cell lung carcinoma cell line (NCI-H460/R). Cancer Biol Ther 7(7):1024–1032

    CAS  PubMed  Google Scholar 

  13. Tortora G, di Isernia G, Sandomenico C, Bianco R, Pomatico G, Pepe S, Bianco AR, Ciardiello F (1997) Synergistic inhibition of growth and induction of apoptosis by 8-chloro-cAMP and paclitaxel or cisplatin in human cancer cells. Cancer Res 57:5107–5111

    CAS  PubMed  Google Scholar 

  14. McDaid HM, Johnston PG (1999) Synergistic interaction between paclitaxel and 8-chloro-adenosine 3′, 5′-monophosphate in human ovarian carcinoma cell lines. Clin Cancer Res 5:215–220

    CAS  PubMed  Google Scholar 

  15. Srivastava RK, Srivastava AR, Cho-Chung YS (1998) Synergistic effects of 8-chlorocyclic-AMP and retinoic acid on induction of apoptosis in Ewing’s sarcoma CHP-100 cells. Clin Cancer Res 4(3):755–761

    CAS  PubMed  Google Scholar 

  16. Jankovic D, Pesic M, Markovic J, Kanazir S, Markovic I, Rakic L, Ruzdijic S (2006) The combination of sulfinosine and 8-ClcAMP induces synergistic cell growth inhibition of the human neuroblastoma cell line in vitro. Invest New Drugs 24:15–25

    Article  CAS  PubMed  Google Scholar 

  17. Milosevic J, Kanazir S, Medic-Mijacevic L, Pejanovic V, Stokic Z, Konjevic G, Ruzdijic S (2002) Sulfinosine-induced cell growth inhibition and apoptosis in human lung carcinomas in vitro. Invest New Drugs 20:229–240

    Article  CAS  PubMed  Google Scholar 

  18. Srivastava RK, Srivastava AR, Cho-Chung YS (2000) Synergistic effects of 8-ClcAMP and retinoic acids in the inhibition of growth and induction of apoptosis in ovarian cancer cells: Induction of retinoic acid receptor beta. Mol Cell Biochem 204:1–9

    Article  CAS  PubMed  Google Scholar 

  19. Tortora G, Ciardiello F, Pepe S, Tagliaferri P, Ruggiero A, Bianco C, Guarrasi R, Miki K, Bianco AR (1995) Phase I clinical study with 8-chloro-cAMP and evaluation of immunological effects in cancer patients. Clin Cancer Res 1(4):377–384

    CAS  PubMed  Google Scholar 

  20. Scala S, Budillon A, Zhan Z, Cho-Chung YS, Jefferson J, Tsokos M, Bates SE (1995) Downregulation of mdr-1 expression by 8-Cl-cAMP in multidrug resistant MCF-7 human breast cancer cells. J Clin Invest 96:1026–1034

    Article  CAS  PubMed  Google Scholar 

  21. Vilpo J, Koski T, Vilpo L (2000) Calcium antagonists potentiate P-glycoproteinindependent anticancer drugs in chronic lymphocytic leukemia cells in vitro. Haematologica 85:806–813

    CAS  PubMed  Google Scholar 

  22. Revankar GR, Hanna NB, Imamura N, Lewis AF, Larson SB, Finch RA, Avery TL, Robins RK (1990) Synthesis and in vivo antitumor activity of 2-amino-9Hpurine-6-sulfenamide, -sulfinamide, and -sulfonamide and related purine ribonucleosides. J Med Chem 33(1):121–128

    Article  CAS  PubMed  Google Scholar 

  23. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55

    Article  CAS  PubMed  Google Scholar 

  24. Ford JM, Bruggemann EP, Pastan I, Gottesman MM, Hait WN (1990) Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res 50:1748–1756

    CAS  PubMed  Google Scholar 

  25. Bösch S, Siavoshian S, Jacquot C, Tomasoni C, Dabouis G, Elanbaloussi Y, Leneel T, More MT, Roussakis C (1997) Correlation between multidrug resistance and the degree of differentiation of non-small-cell bronchopulmonary carcinoma (NSCLC) in vitro and in vivo. Anticancer Res 17(6D):4595–4598

    PubMed  Google Scholar 

  26. Wong H, Anderson WD, Cheng T, Riabowol KT (1994) Monitoring mRNA expression by polymerase chain reaction: the “primer-dropping” method. Anal Biochem 223:251–258

    Article  CAS  PubMed  Google Scholar 

  27. Gupte RS, Weng Y, Liu L, Lee MYWT (2005) The second subunit of the replication factor C complex (RFC40) and the regulatory subunit (RIα) of protein kinase A form a protein complex promoting cell survival. Cell Cycle 4:323–329

    CAS  PubMed  Google Scholar 

  28. Boik JC, Newman RA (2008) A classification model to predict synergism/antagonism of cytotoxic mixtures using protein-drug docking scores. BMC Pharmacol 8:13

    Article  PubMed  Google Scholar 

  29. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, Danesi R (2005) Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 68(1):110–118

    CAS  PubMed  Google Scholar 

  30. Berridge M, Lipp P, Bootman M (1999) Calcium signalling. Curr Biol 9:R157–R159

    Article  CAS  PubMed  Google Scholar 

  31. Trompier D, Chang XB, Barattin R, du Moulinet D’Hardemare A, Di Pietro A, Baubichon-Cortay H (2004) Verapamil and its derivative trigger apoptosis through glutathione extrusion by multidrug resistance protein MRP1. Cancer Res 64:4950–4956

    Article  CAS  PubMed  Google Scholar 

  32. Avery TL, Finch RA, Vasquez KM, Radparvar S, Hanna NB, Revanker GR et al (1990) Chemotherapeutic characterization in mice of 2-amino-9-beta-Dribofuranosylpurine-6-sulfinamide (sulfinosine), a novel purine nucleoside with unique antitumor properties. Cancer Res 50:2625–2630

    CAS  PubMed  Google Scholar 

Download references

Acknowledgement

This work was supported by grant #143009B from the Ministry of Science and Technological Development, Republic of Serbia.

Author information

Authors and Affiliations

  1. Institute for Biological Research, Department of Neurobiology, Laboratory of Molecular Neurobiology, University of Belgrade, Bulevar Despota Stefana 142, 11060, Belgrade, Republic of Serbia

    Milica Pešić, Ana Podolski & Sabera Ruždijić

  2. Serbian Academy of Sciences and Arts, Knez Mihailova 35, 11000, Belgrade, Republic of Serbia

    Ljubiša Rakić

Authors
  1. Milica Pešić
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ana Podolski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ljubiša Rakić
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sabera Ruždijić
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sabera Ruždijić.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pešić, M., Podolski, A., Rakić, L. et al. Purine analogs sensitize the multidrug resistant cell line (NCI-H460/R) to doxorubicin and stimulate the cell growth inhibitory effect of verapamil. Invest New Drugs 28, 482–492 (2010). https://doi.org/10.1007/s10637-009-9277-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-009-9277-x

Keywords

Search

Navigation